Table 1.
Baseline characteristics of the patients
| Patient number | Sex/Age | Body weight (kg) | Body mass index | Duration of psoriasis (yr) | Baseline PASI score (%) | Baseline BSA (%) | Baseline PGA | UMSC Dose/kg (×106) | Previous treatment |
|---|---|---|---|---|---|---|---|---|---|
| 2019/2–2019/8 (n = 5) | |||||||||
| S01 | F/32 | 54 | 20.3 | 25 | 30.7 | 34.6 | 5 | 1.5 | MTX, CsA, AcI, PUVA |
| S02 | M/55 | 61 | 22.6 | 10 | 26.6 | 32.8 | 5 | 1.5 | AcI, IL-17 monoclonal antibody, TA |
| S03 | M/29 | 82 | 26.8 | 14 | 20.4 | 42.0 | 4 | 1.5 | TCM, PUVA, TA |
| S04 | F/39 | 51 | 20.2 | 27 | 25.6 | 67.0 | 5 | 1.5 | MTX, AcI, PUVA, levocetirizine, Yisaipu |
| S05 | M/44 | 76 | 26.3 | 9 | 17.1 | 17.5 | 4 | 1.5 | TCM |
| 2019/9–2020/8 (n = 12) | |||||||||
| S09 | F/50 | 70 | 26 | 32 | 13.5 | 19.0 | 4 | 1.5 | MTX, TCM, PUVA, TA |
| S10 | M/53 | 67 | 23.2 | 9 | 15.2 | 20.0 | 4 | 1.5 | TCM, TA |
| S11 | M/55 | 60 | 20.8 | 30 | 13.2 | 12.3 | 3 | 1.5 | MTX, Folic acid, levocetirizine, Ssg, TA |
| S12 | F/32 | 61 | 24.4 | 19 | 11.3 | 18.1 | 4 | 2.0 | TCM, tirixizine, TA |
| S13 | M/34 | 63 | 23.1 | 20 | 10.8 | 12.9 | 4 | 2.0 | TCM, TA |
| S14 | F/30 | 55 | 20.8 | 7 | 16.9 | 28.8 | 4 | 2.0 | Ssg, TCM, TA |
| S15 | F/39 | 62 | 25.1 | 10 | 24.4 | 32.0 | 5 | 2.5 | AcI-A, TA |
| S16 | M/46 | 76 | 31.2 | 20 | 23.8 | 51.1 | 4 | 2.5 | AcI, Ssg, TA |
| S17 | F/37 | 50 | 20.8 | 7 | 13.4 | 12.9 | 4 | 2.5 | AcI, TA |
| S18 | F/31 | 51 | 21.2 | 10 | 16.4 | 15.1 | 4 | 3.0 | Ssg, TA |
| S19 | F/48 | 80 | 27.3 | 16 | 15.4 | 13.8 | 4 | 3.0 | CsA, AcI, TA |
| S20 | M/35 | 66 | 22.5 | 4 | 15.0 | 12.6 | 4 | 3.0 | Ssg, PUVA, TA |
PASI psoriasis area and severity index, BSA body surface area, PGA physicians’ global assessment; Only systemic previous therapies: MTX methotrexate, CsA cyclosporin, AcI Acitretin; TA Topical agents, TCM Traditional Chinese medicine; Ssg Silver shavings granule